JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Decheng Capital, a ten-percent owner in BeyondSpring Inc (NASDAQ:BYSI), has reported selling 4,900 shares of the company’s stock for approximately $9,800. The sales occurred in two transactions on August 14 and 15, 2025, with prices ranging from $2.00 to $2.01. The stock, currently trading at $2.02, has shown strong momentum with a 24% gain year-to-date, according to InvestingPro data.
The first sale, on August 14, involved 2,000 shares. The second sale, on August 15, involved 2,900 shares.
Following these transactions, Decheng Capital China Life Sciences USD Fund III, L.P. directly holds 1,974,172 shares. Decheng Capital China Life Sciences USD Fund II, L.P. holds 1,617,409 shares, and Decheng Capital Global Healthcare Fund (Master), LP holds 891,734 shares in BeyondSpring.
In other recent news, BeyondSpring Inc. has reported promising results from its clinical trials involving its lead drug, Plinabulin. A study published in Med (Cell Press) demonstrated that Plinabulin, when used in combination with radiation and checkpoint inhibitors, showed efficacy in patients who had previously failed immune checkpoint inhibitor therapy. The trial showed a 23% objective response rate and a 54% disease control rate in non-irradiated lesions among the patients. Additionally, interim phase 2 data for a study on metastatic non-small cell lung cancer (NSCLC) patients revealed encouraging results for a combination therapy involving Plinabulin, pembrolizumab, and docetaxel. This study, presented at the American Society of Clinical Oncology Annual Meeting, reported a median progression-free survival of 6.8 months, nearly doubling the standard care’s 3.7 months. The disease control rate was 77.3%, with a 15-month overall survival rate of 78%. BeyondSpring has also scheduled its 2025 annual shareholder meeting for September 15, with proposals for inclusion in the proxy statement due by July 14, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.